Tivic Shareholders Approve Key Proposals in Support of Strategic Transformation; Lisa Wolf Appointed Permanent CFO
Company provides additional management updates
The approved proposals included the issuance of equity as a form of payment pursuant to Tivic鈥檚 worldwide exclusive license agreement for Entolimod鈩� and Entolasta鈩�, including for uses in acute radiation syndrome, neutropenia and other indications in oncology and hematology. Shareholders also approved the Company鈥檚 issuance of equity in accordance with previously announced financing arrangements. In each case, Tivic was required to obtain shareholder approval under Nasdaq listing rules.
鈥淲e have established a strong foundation for Tivic鈥檚 expansion into biopharmaceutical markets -- starting with commercialization of Entolimod for two large-market indications,鈥� stated Tivic CEO, Jennifer Ernst. 鈥淲e have already received strong customer interest in Entolimod鈥檚 national defense applications as a potential treatment for acute radiation syndrome. We have also secured exclusive rights for its use in the treatment of neutropenia, a market currently estimated to reach nearly
Leadership Update
鈥淚 am also pleased to announce that Lisa Wolf, who has served as our Interim Chief Financial Officer for the last nine months and in senior leadership roles on Tivic鈥檚 finance team for more than three years, yesterday assumed the official role of our permanent Chief Financial Officer,鈥� said Ernst. 鈥淟isa has been instrumental in supporting the financial architecture of our expansion and I look forward to continuing to work closely with her through this exciting period.
鈥淚 also want to thank, Blake Gurfein, who served as our Chief Scientific Officer for eight years, spearheading the development and commercialization of ClearUP, our first FDA-approved product, and our expansion into our Vagus Nerve Stimulation program. I look forward to continuing to work with Blake as he steps down from his CSO role and assumes a consultant role with Tivic, in which he will continue to support the VNS program, including product and intellectual property development.鈥�
About Tivic Health Systems, Inc.
Tivic Health seeks to treat underserved medical conditions through biochemical and bioelectric therapies that modulate patients鈥� immune system. The company's lead biopharma product candidate, the TLR5 agonist Entolimod鈩� to treat ARS, has been granted Fast Track and Orphan Drug designation by the FDA. Tivic Health's bioelectronic program is developing non-invasive medical devices that personalize key stimulation to modulate the pathways implicated in many prevalent and debilitating diseases.
Tivic Health's first FDA approved product ClearUP鈩� is proven to treat sinus pain and pressure, and is available through online retailers and commercial distributors. For more information about Tivic Health, visit:
Forward-Looking Statements
This press release may contain 鈥渇orward-looking statements鈥� that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 鈥渁nticipate,鈥� 鈥渂elieve,鈥� 鈥渃ontemplate,鈥� 鈥渃ould,鈥� 鈥渆stimate,鈥� 鈥渆xpect,鈥� 鈥渋ntend,鈥� 鈥渟eek,鈥� 鈥渕ay,鈥� 鈥渕ight,鈥� 鈥減lan,鈥� 鈥減otential,鈥� 鈥減redict,鈥� 鈥減roject,鈥� 鈥渢arget,鈥� 鈥渁im,鈥� 鈥渟hould,鈥� 鈥渨ill,鈥� 鈥渨ould,鈥� or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.鈥檚 current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate, including as a result of the company鈥檚 interactions with and guidance from the FDA and other regulatory authorities; changes to the company鈥檚 relationship with its partners; failure to obtain FDA or similar clearances or approvals and noncompliance with FDA or similar regulations; the company鈥檚 future development of its ncVNS treatment, Entolimod and Entolasta; changes to the company鈥檚 business strategy; timing and success of clinical trials and study results, including the ncVNS optimization study with The Feinstein Institute of Bioelectronic Medicine; regulatory requirements and pathways for approval; changes in the markets and industries in which the company does business; consummation of any strategic transactions; the company鈥檚 need for, and ability to secure when needed, additional working capital; the company鈥檚 ability to maintain its Nasdaq listing; and changes in tariffs, inflation, legal, regulatory, political and economic risks. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health鈥檚 filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 21, 2025, under the heading 鈥淩isk Factors鈥�, as well as the company鈥檚 subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and the company undertakes no duty to update such information except as required by applicable law.
View source version on businesswire.com:
Investor Contact:
Hanover International, Inc.
[email protected]
Media Contact:
Deanne Eagle or Laura Min Jackson
[email protected]
Source: Tivic Health Systems, Inc.
